Today: 21 May 2026
USA Rare Earth (USAR) stock jumps as U.S. backs $1.6 billion CHIPS-linked funding plan
26 January 2026
2 mins read

USA Rare Earth (USAR) stock jumps as U.S. backs $1.6 billion CHIPS-linked funding plan

New York, January 26, 2026, 13:09 EST — Regular session

  • Shares of USA Rare Earth jumped roughly 17% in early afternoon trading following the announcement of a proposed U.S. funding package alongside a $1.5 billion PIPE.
  • The company said the plan would back a Texas rare earth project along with an Oklahoma magnet facility connected to defense and high-tech needs.
  • Investors are focused on whether the non-binding U.S. deal will lead to final agreements and if new equity raises come next.

Shares of USA Rare Earth jumped roughly 17% to $28.94 in early Monday afternoon trading, continuing a choppy stretch for the rare-earths company.

The company announced a non-binding letter of intent with the U.S. Department of Commerce’s CHIPS Program, involving $277 million in proposed federal funding and a $1.3 billion senior secured loan. It also includes a $1.5 billion private investment in public equity, or PIPE. CEO Barbara Humpton described the move as a “transformative step,” while Commerce Secretary Howard Lutnick said the investment would strengthen supply chains, making them “resilient” and less dependent on foreign countries.

Timing is key as Washington ramps up its focus on critical minerals as a national security concern. The goal: develop supply chains for magnets and specialty metals—essential in weapons systems, chips, and electric motors—outside of China. The Commerce Department’s latest action fits into a wider effort to boost domestic mining and processing capacity.

A regulatory filing revealed the company inked a securities purchase agreement for a private placement of 69,767,442 common shares, raising roughly $1.5 billion at $21.50 per share. The deal is set to close on January 28. The filing also detailed terms for the anticipated U.S. transaction, noting the proposed $1.3 billion loan would carry a 15-year term and an expected interest rate of Treasury plus 150 basis points, or 1.5 percentage points.

The U.S. package includes equity components. According to the company’s terms, the government would get common shares and warrants — which allow the holder to purchase stock at a predetermined price in the future — as part of the proposed awards and loan.

USA Rare Earth pointed to a lengthy list of hurdles before reaching definitive agreements, such as raising non-federal capital and locking in memoranda of understanding with semiconductor end-users or midstream players, among other key steps.

Reuters reported the Commerce Department will take a 10% stake, noting the deal excludes a government-backed price floor like the one MP Materials secured in an earlier federal investment. On a call, Humpton told investors the company’s early sales strategy was driven by the “cost of having access to nothing.” Reuters

The company is working on a “mine-to-magnet” supply chain. It plans to start commercial production at its Round Top deposit in Texas by 2028, while its magnet facility in Stillwater, Oklahoma, is set to finish commissioning in early 2026.

Preliminary figures also showed cash and cash equivalents exceeding $350 million by the end of 2025. The company anticipates annual operating expenses and operating losses between $56 million and $62 million, alongside capital spending of $37 million to $43 million.

Shares of MP Materials fell roughly 6.5% by the close, despite a strong jump at the session’s start. The drop rippled through its sector peers.

The risk remains clear. The U.S. deal is just a letter of intent, with funding expected to arrive in stages linked to milestones. The company has been upfront about requiring additional capital and operating without signed customers.

The next key date is January 28, when the company anticipates closing the PIPE. Traders will then turn their attention to finalizing government package agreements, along with any customer MOUs and potential extra financing moves that might surface before quarter-end.

Stock Market Today

  • IonQ Stock Analysis: Evaluate Quantum Computing Investment Potential
    May 20, 2026, 9:03 PM EDT. IonQ, a quantum computing firm, is not currently recommended by Motley Fool's Stock Advisor, which recently highlighted its top 10 stock picks excluding IonQ. The advisor's past picks like Netflix and Nvidia yielded returns exceeding 48,000% and 135,000%, respectively, far outperforming the S&P 500's 206% average. Motley Fool holds positions in IonQ and may benefit financially from related promotions, disclosed according to regulatory policy. Investors should weigh the lack of IonQ's inclusion in the advisor's latest list against the broader context of quantum technology's growth prospects.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Amazon stock price slips as AWS lands Nationwide deal and earnings loom
Previous Story

Amazon stock price slips as AWS lands Nationwide deal and earnings loom

Dow Jones today: Apple, Cisco lift the index as Fed decision and Big Tech earnings loom
Next Story

Dow Jones today: Apple, Cisco lift the index as Fed decision and Big Tech earnings loom

Go toTop